Cited in:


This article has been cited by:

  1. 1
    S. Akamatsu, C. N. Hayes, M. Tsuge, E. Murakami, N. Hiraga, H. Abe, D. Miki, M. Imamura, H. Ochi, K. Chayama, Ribavirin dose reduction during telaprevir/ribavirin/peg-interferon therapy overcomes the effect of the ITPA gene polymorphism, Journal of Viral Hepatitis, 2015, 22, 2
  2. 2
    Pierre Pradat, Victor Virlogeux, Marie-Claude Gagnieu, Fabien Zoulim, François Bailly, Ribavirin at the Era of Novel Direct Antiviral Agents for the Treatment of Hepatitis C Virus Infection: Relevance of Pharmacological Monitoring, Advances in Hepatology, 2014, 2014, 1


  3. 3
    B. Maasoumy, K. Port, B. Calle Serrano, A. A. Markova, L. Sollik, M. P. Manns, M. Cornberg, H. Wedemeyer, The clinical significance of drug–drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C, Alimentary Pharmacology & Therapeutics, 2013, 38, 11-12